SecBot SecBot
SECBOTREPLAY Home › Report › XERS

XERS · Analysis based on filing metadata only, document content was…

Xeris Biopharma Holdings, Inc. · 8-K filed Feb 27, 2026 at 06:05 ET

At the news

NEUTRALIMPACT 3/10

8-K filed Feb 27, 2026 at 06:05 ET

Analysis based on filing metadata only, document content was unavailable. The 8-K filing for Xeris Biopharma Holdings, Inc. (XERS) includes Items 7.01 (Regulation FD Disclosure) and 9.01 (Financial Statements and Exhibits), suggesting a possible investor presentation or public disclosure of material information, but no specific details or financial data are accessible to confirm content or implications.

  • Filing is an 8-K for Xeris Biopharma Holdings, Inc. (XERS)
  • Items reported: 7.01 (Regulation FD Disclosure) and 9.01 (Financial Statements and Exhibits)
  • No document content available to verify disclosures, financials, or strategic updates
  • Exhibit 99.1 (press release or presentation) was likely filed but not accessible

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access